Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Abstract Background Parkinson’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Parkinson’s disease, but drug discovery is challenged by lack of in vivo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kevin S. Chen, Krystal Menezes, Jarlath B. Rodgers, Darren M. O’Hara, Nhat Tran, Kazuko Fujisawa, Seiya Ishikura, Shahin Khodaei, Hien Chau, Anna Cranston, Minesh Kapadia, Grishma Pawar, Susan Ping, Aldis Krizus, Alix Lacoste, Scott Spangler, Naomi P. Visanji, Connie Marras, Nour K. Majbour, Omar M. A. El-Agnaf, Andres M. Lozano, Joseph Culotti, Satoshi Suo, William S. Ryu, Suneil K. Kalia, Lorraine V. Kalia
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Alpha-synuclein Animal model Artificial intelligence Drug discovery Machine learning Natural language processing Neurology. Diseases of the nervous system RC346-429 Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/1a816ab50aad45a9bf006d7c91b18cff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Ejemplares similares